The move impacts everything from major food recalls to vital public health warnings. Experts explain what that means for you ...

The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...

OneBlood is the first blood center to get full FDA approval to give high-titer COVID-19 convalescent plasma to those with COVID-19 who are also immunocompromised.

A new experimental vaccine developed by researchers at MIT and Caltech could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that ...

A Texas woman was sentenced Wednesday to one year of probation after she admitted to using fake names to smuggle an unapproved drug from China and Hong Kong into the United to treat a fatal cat ...

President Donald Trump's initial executive orders target previous efforts to reduce health care costs, pandemic preparedness, ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

Along with claiming the lives of 1.2 million Americans, the COVID-19 pandemic has been described as a mass disabling event.

Long COVID remains a major health challenge for millions of people, with symptoms like brain fog lingering for months after the initial infection. However, a new study from UCSF offers some hope.

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.